恒济医药

Jiangsu Hengji Pharmaceutical is a prominent Chinese pharmaceutical company and a core subsidiary of Jiangsu Hengrui Pharmaceuticals. Based in Lianyungang, the company serves as a major manufacturing and research base for the Hengrui group, focusing on high-end generic drugs and innovative medicines. Its portfolio covers a wide range of therapeutic areas, including oncology, metabolic disorders, and cardiovascular health. The company operates state-of-the-art GMP-certified facilities for the production of tablets, capsules, and injections. Jiangsu Hengji is responsible for the commercialization and production of several key products, such as the VEGFR inhibitor apatinib. As an integral part of the Hengrui ecosystem, it plays a vital role in the group's domestic market leadership and global expansion efforts.